Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients

NCT04325581 · Completed

Last updated 2026-05-28

This clinical trial is testing whether adding the medication liraglutide to laparoscopic sleeve gastrectomy surgery helps with weight loss in obese patients.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 16 people

Who can join Ages 18–65 · all sexes

Timeline Started 2016-08 · est. completion 2018-12

What this study is testing ClinicalTrials.gov NCT04325581 ↗

Description as written by the study sponsor.

Investigators postulate that the metabolic effects of LSG would be augmented with the use of liraglutide leading to additional excess weight loss, improved glucose homeostasis, decreased intrapancreatic and intrahepatic fat than either of them individually. However there are no studies till date which have evaluated the combined effects of two modalities of weight loss on the above mentioned parameters. This study plans to compare the effects of liraglutide in post- LSG obese patients in a placebo controlled design.

Treatments tested

Liraglutide 6 MG/ML also known as Calorie restricted diet Drug

Liraglutide in incremental dose upto maximum of 1.8 mg per day SC daily
Placebos also known as Calorie restricted diet Drug

Normal Saline SC daily

Main thing measured	Incretin change
Sponsor	Post Graduate Institute of Medical Education and Research, Chandigarh
Conditions studied	Weight Loss
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04325581 ↗